Source – Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study[/caption]
National Medicines Symposium 2024 speakers (L to R): Steve Waller, Professor Jennifer Martin, Professor Libby Roughead, Tegan Taylor[/caption]
This CPD activity is sponsored by Reckitt. All content is the true, accurate and independent opinion of the speakers and the views expressed are entirely their own.[/caption]
Are you up to speed on COVID-19 antiviral eligibility changes?
On 11 July, millions of Australians gained access to oral COVID-19 antiviral treatments after the eligibility criteria widened significantly.
Carving one’s own path as a consultant pharmacist
Geraldine Moses FPS wears many hats. She’s a hospital-based drug information consultant and clinical pharmacist, and provider of the Australian Dental Association’s (ADA) national...
New TG cushions the blow of ABX shortages
A new Therapeutic Guidelines summary table, ensures patients can receive appropriate treatments when first-line options are unavailable.
Reusable Respimat for Spiriva and Spiolto
Australia’s only soft mist inhaler, Respimat, is now available as a reusable device and is included on the PBS for asthma or COPD patients.
Managing hand osteoarthritis – the latest evidence
Despite being one of the most common phenotypes with a high clinical burden, hand OA was long regarded as a ‘forgotten disease’, with limited clinical evidence to guide treatment recommendations.
UTI pilot decision a step forward in pharmacy prescribing
Queensland pharmacies that took part in the 2-year Urinary Tract Infection Pharmacy Pilot – Queensland can continue indefinitely.
